102 related articles for article (PubMed ID: 20545466)
1. Increased expression of elongation factor-1α is significantly correlated with poor prognosis of human prostate cancer.
Liu H; Ding J; Chen F; Fan B; Gao N; Yang Z; Qi L
Scand J Urol Nephrol; 2010 Nov; 44(5):277-83. PubMed ID: 20545466
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer.
Zhang YF; Guan YB; Yang B; Wu HY; Dai YT; Zhang SJ; Wang JP; Anoopkumar-Dukie S; Davey AK; Sun ZY
Chin Med J (Engl); 2011 Dec; 124(24):4345-9. PubMed ID: 22340411
[TBL] [Abstract][Full Text] [Related]
3. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
4. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification.
Ploussard G; Masson-Lecomte A; Beauval JB; Ouzzane A; Bonniol R; Buge F; Fadli S; Rouprêt M; Rebillard X; Gaschignard N; Pfister C; Villers A; Soulié M; Salomon L;
Urology; 2011 Sep; 78(3):607-13. PubMed ID: 21783233
[TBL] [Abstract][Full Text] [Related]
5. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
7. Low p27 expression predicts poor disease-free survival in patients with prostate cancer.
Yang RM; Naitoh J; Murphy M; Wang HJ; Phillipson J; deKernion JB; Loda M; Reiter RE
J Urol; 1998 Mar; 159(3):941-5. PubMed ID: 9474188
[TBL] [Abstract][Full Text] [Related]
8. Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ.
Hou H; Chen W; Zhao L; Zuo Q; Zhang G; Zhang X; Wang H; Gong H; Li X; Wang M; Wang Y; Li X
J Clin Pathol; 2012 Dec; 65(12):1088-96. PubMed ID: 22944623
[TBL] [Abstract][Full Text] [Related]
9. L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.
Koutalellis G; Stravodimos K; Avgeris M; Mavridis K; Scorilas A; Lazaris A; Constantinides C
BJU Int; 2012 Sep; 110(6 Pt B):E267-73. PubMed ID: 22571720
[TBL] [Abstract][Full Text] [Related]
10. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
11. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD147 is associated with prostate cancer progression.
Zhong WD; Liang YX; Lin SX; Li L; He HC; Bi XC; Han ZD; Dai QS; Ye YK; Chen QB; Wang YS; Zeng GH; Zhu G; Zhang Z; Chen ZN; Wu CL
Int J Cancer; 2012 Jan; 130(2):300-8. PubMed ID: 21328337
[TBL] [Abstract][Full Text] [Related]
13. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
[TBL] [Abstract][Full Text] [Related]
14. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
15. [Metastatic progression, cancer-specific mortality and need for secondary treatments in patients with clinically high-risk prostate cancer treated initially with radical prostatectomy].
Rubio-Briones J; Iborra I; Trassierra M; Collado A; Casanova J; Gómez-Ferrer A; Ricós JV; Monrós JL; Dumont R; Solsona E
Actas Urol Esp; 2010 Jul; 34(7):610-7. PubMed ID: 20540878
[TBL] [Abstract][Full Text] [Related]
16. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
17. [Factors influencing the progression-free survival time of prostate cancer patients after endocrine therapy].
Guan YB; Zhang YF; Wen H; Zhou SQ; Dai YT
Zhonghua Nan Ke Xue; 2009 Sep; 15(9):801-5. PubMed ID: 19947562
[TBL] [Abstract][Full Text] [Related]
18. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
Fu Z; Kitagawa Y; Shen R; Shah R; Mehra R; Rhodes D; Keller PJ; Mizokami A; Dunn R; Chinnaiyan AM; Yao Z; Keller ET
Prostate; 2006 Feb; 66(3):248-56. PubMed ID: 16175585
[TBL] [Abstract][Full Text] [Related]
19. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW
J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308
[TBL] [Abstract][Full Text] [Related]
20. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.
Huang SP; Bao BY; Wu MT; Choueiri TK; Goggins WB; Liu CC; Huang CY; Pu YS; Yu CC; Wu TT; Huang CN; Huang CH; Wu WJ
Aging Male; 2012 Mar; 15(1):34-41. PubMed ID: 21615239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
